FDA approves an Instructions for Use for a single-dose Ozempic prefilled syringe

The FDA-approved prescribing information for Ozempic (semaglutide), revised in May 2026, now lists a single-dose prefilled syringe alongside the familiar dial pen ^[1][2]. The syringe comes in three strengths — 0.25 mg, 0.5 mg, and 1 mg per 0.5 mL — and is packaged four to a carton ^[1][2]. This marks the first Ozempic presentation that is not a multi-dose dial pen ^[1].

The syringe uses a fixed, single dose per device rather than a dial-a-dose mechanism. According to the label's dosage forms and strengths section, each syringe delivers one of the three listed strengths, unlike the pens, which hold multiple weekly doses drawn from a larger cartridge — for example, the 2 mg/3 mL pen supports four doses of 0.25 mg and two doses of 0.5 mg, or four doses of 0.5 mg ^[1][2]. The pens also come in higher-strength versions for 1 mg and 2 mg maintenance doses that are not available in syringe form on this label ^[1][2].

The label's dosing schedule itself has not changed: patients start at 0.25 mg once weekly for four weeks, then move to 0.5 mg, with possible increases to 1 mg and, for glycemic control only, up to 2 mg once weekly, each step requiring at least four weeks on the prior dose ^[1][2]. For patients using Ozempic to reduce the risk of kidney disease progression, the recommended maintenance dose remains 1 mg weekly after at least four weeks at 0.5 mg ^[1][2]. Injections are still given in the abdomen, thigh, or upper arm, and a missed dose can still be given within five days ^[1][2].

The label's most recent major change before this one was an update to the gastrointestinal warning section in October 2025 ^[1][2]. That warning remains in place: Ozempic use has been linked to gastrointestinal reactions, sometimes severe, and the drug is not recommended for people with severe gastroparesis ^[1][2]. The boxed warning about thyroid C-cell tumors seen in rodent studies, and the contraindication for people with a personal or family history of medullary thyroid carcinoma or MEN 2, also carry over unchanged to the new syringe presentation ^[1][2].

Why it matters for patients

A prefilled syringe is a different physical object than a pen, and the sources note it relies on a pinched skinfold and a 45-degree injection angle rather than a dial-based dose counter, with a shorter 28-day storage window at 8 to 30°C compared with the pen's 56 days. That shorter shelf life means people using the syringe would need to track expiration more closely than pen users do. For patients who have only ever used the Ozempic pen, a switch to a prefilled syringe would mean learning a new injection technique rather than relying on the pen's click-based dosing.

The label does not explain why Novo Nordisk added this presentation, whether it is meant to replace the pen, or which patients it is intended for. It also does not say when the syringe will actually reach pharmacies, what it will cost, or whether insurance coverage will differ from the pen. Those details are not yet known from the sources reviewed here.

All of the drug's core safety information stays the same across presentations: the same boxed warning, the same contraindications, and the same list of common side effects, including nausea, vomiting, diarrhea, abdominal pain, and constipation ^[1][2]. So the change described here is about how the dose is packaged and delivered, not about who the drug is approved for or what risks it carries.

What happens next

The revised label and its new Instructions for Use were marked approved as of May 2026 ^[1][2]. The sources do not specify a retail launch date, pricing, or whether the syringe will be offered as an alternative to the pen or in limited distribution. Patients and pharmacists will likely need to watch for further updates from Novo Nordisk or the FDA on availability.